Clinical Trial Update: Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease [Phase 4]

View source ↗

Summary

Phase 4 clinical trial sponsored by LivaNova evaluating prevention of atrial arrhythmias in patients without atrioventricular conduction disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brady-tachycardia Syndrome
• Sinus Node Dysfunction

Snippet

Sponsor: LivaNova | Conditions: Sinus Node Dysfunction, Brady Tachy Syndrome | Phase 4 | Status: COMPLETED